New Feature: 'QbD Process Development Function' Added to Epistra Accelerate
Simultaneously Understand Robust Conditions and Design Space
The QbD Process Development function addresses the following challenges in production condition determination:
- Challenge 1: “Performance becomes unstable due to slight experimental variability or scale-up changes, leading to poor reproducibility”
- Challenge 2: “Determining acceptable ranges and design space requires significant time and resources”
These challenges caused delays and cost increases when condition revisions were needed during later development phases.
Streamlining the Research Timeline
The new function optimizes both condition exploration and design space estimation, significantly shortening development timelines.
Case Study: Joint Research with Astellas Pharma
Joint research with Astellas Pharma achieved “50- to 100-fold efficiency improvement” and design space estimation. The results were presented at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine, demonstrating the integration of AI and robotics in automating stem cell culture processes. Key achievements include a “50- to 100-fold increase in NK cell yield” and successful design space estimation in just three experiments.
Two Solution Approaches
Robust Optimization
AI identifies conditions that maintain stable quality even with parameter variations. “Robust conditions” are automatically derived from optimization data.
Design Space Visualization
Acceptable parameter ranges are displayed as contour plots, enabling practical Quality by Design implementation with fewer experiments than conventional approaches.
Related Articles
Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of Japan
Epistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
Cell Culture Optimization Software 'CellTune Ver.2' Launches Globally
Epistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine Seminar
On June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.